Imunexus’ Product Pipeline
Imunexus has a multi-tier multispecific drug development strategy with seven commercially compelling potential drug candidates. Five of these are based on marketed antibody therapeutics and two are unique bispecific investigational drugs. These candidates have all been synthesized in our laboratory and had a model Imunexin inserted to validate the manufacturability of the bi-specific constructs. Our half-life extending Imunexin has already been inserted into one of these candidates.
When developing new drugs, Imunexus capitalises on the strengths of its potential multispecific products while reducing risk at all stages. For this reason, Imunexus selects products for its pipeline based on a number of key commercial factors including:
- the positioning of a marketed antibody in the market, including patient accessibility
- the clinical and safety dossier of a non-marketed, but clinically validated, antibody
- the potential for orphan or breakthrough therapy designation
- the clinical (efficacy and tolerability) improvement potential
- limited competition and a wide freedom to operate
- the patent status of the parent antibody, and
- other commercial factors
The company has re-engineered 6 antibodies and one globular protein drug candidates with evaluative (non-clinical) ImunexinsTM validating the technology. We have identified two unique families of ImunexinsTM, one activating the immune system and the other mediating the length of time an antibody remains in the bloodstream (serum half-life). We aim to link these ImunexinsTM to select marketed or clinically validated antibodies and undertake preclinical trials. Upon the successful completion of preclinical studies, we aim to progress our clinical candidates into human clinical trials.
The applications for the ImunexinTM platform are broad and flexible so we are not limited to the activation of the immune system and serum half-life extension, with other ImunexinTM families, binding other targets, for different improvement modes are also being developed.